Clinical data before onset of treatment with interferon-β1a (Rebif)
| Patient | Age/ sex | Diagnosis | Onset of symptoms | Initially affected motor nerves | Duration of illness(y) | Previous treatments | Anti-GM1 antibodies |
|---|---|---|---|---|---|---|---|
| 1 | 39/M | MMN | UL/D/A | L Radial/L Ulnar | 9 | IVIg1/Cyclophos (2x)2a/Predn3 | + |
| R Radial | Cyclophos2b+Predn3/IVIg1+Mpredn4 | (1 : 12800) | |||||
| 2 | 60/F | MMN | UL/D/A | R Median/L Ulnar | 8 | IVIg (3x)1 | − |
| 3 | 53/F | MMN | UL/D/A | L Ulnar | 7 | IVIg (2x)1/IVIg1+Mpredn4 | + |
| (1 : 200) | |||||||
| 4 | 54/M | CIDP | LL/D>P/S | L+R Posterior tibial and peroneal | 9 | IVIg (2x)1/IVIg1+Mpredn4/Predn3/PE5
Cyclophos2a+Predn3/Cyclophos2c | + (1 : 12800) |
MMN=multifocal motor neuropathy; CIDP=chronic inflammatory demyelinating polyneuropathy; UL=upper limb; LL=lower limb; D=distal; P=proximal; A=asymmetric; S=symmetric; L=left; R=right; IVIg=intravenous immunoglobulins; Cyclophos=cyclophosphamide; MPredn=methylprednisolone; PE=plasma exchange; 1=0.4 g/kg body weight/day for 5 days; 2a=0.5 g/day intravenously for 14 days; 2b=0.15 g/day orally for half a year;2c=monthly 0.5 g/day orally for 4 days for 6 months;3=60–80 mg/day orally for 6 weeks, thereafter tapering to zero in 6 months; 4=0.5g /day for 5 days; 5=2 exchange sessions (each 2.5 litres plasma)/week for 5 consecutive weeks.